HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thomas C Chen Selected Research

Nelfinavir (Viracept)

12/2012Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors.
11/2012Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
9/2009Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress.
11/2007HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.
1/2007Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Thomas C Chen Research Topics

Disease

88Neoplasms (Cancer)
12/2021 - 01/2003
47Glioma (Gliomas)
01/2021 - 05/2002
32Glioblastoma (Glioblastoma Multiforme)
01/2022 - 01/2003
20Brain Neoplasms (Brain Tumor)
10/2021 - 04/2005
6Breast Neoplasms (Breast Cancer)
12/2021 - 09/2009
6Meningioma (Meningiomas)
04/2020 - 01/2007
4Neoplasm Metastasis (Metastasis)
10/2021 - 09/2010
4Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2019 - 03/2016
4Multiple Myeloma
03/2019 - 12/2005
3Hypoxia (Hypoxemia)
10/2020 - 01/2013
3Nasopharyngeal Carcinoma
06/2019 - 08/2015
3Melanoma (Melanoma, Malignant)
12/2018 - 03/2015
2Infections
01/2022 - 12/2005
2Necrosis
01/2017 - 09/2014
2Triple Negative Breast Neoplasms
03/2016 - 01/2013
2Vascular Diseases (Vascular Disease)
05/2014 - 01/2014
2Carcinogenesis
01/2013 - 05/2011
2Hydrocephalus (Hydrocephaly)
09/2010 - 11/2006

Drug/Important Bio-Agent (IBA)

32Temozolomide (Temodar)FDA LinkGeneric
01/2022 - 04/2006
28Pharmaceutical PreparationsIBA
12/2021 - 05/2002
24perillyl alcoholIBA
12/2021 - 11/2012
12NEO212IBA
07/2021 - 08/2014
11Celecoxib (Celebrex)FDA Link
12/2012 - 01/2004
8DNA (Deoxyribonucleic Acid)IBA
01/2020 - 03/2011
7Proteins (Proteins, Gene)FDA Link
01/2020 - 01/2007
7Endoplasmic Reticulum Chaperone BiPIBA
01/2013 - 04/2007
7Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
12/2012 - 01/2004
6Bevacizumab (Avastin)FDA Link
01/2022 - 09/2014
6IntegrinsIBA
11/2020 - 01/2003
6Alkylating AgentsIBA
11/2018 - 03/2011
6VaccinesIBA
08/2018 - 03/2008
6Irinotecan (Camptosar)FDA LinkGeneric
03/2015 - 05/2003
5Antineoplastic Agents (Antineoplastics)IBA
11/2020 - 07/2005
5DisintegrinsIBA
11/2020 - 01/2003
5Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2019 - 04/2005
5Nelfinavir (Viracept)FDA Link
12/2012 - 01/2007
52,5-dimethylcelecoxibIBA
12/2012 - 04/2007
4Snake Venoms (Snake Venom)IBA
11/2020 - 01/2003
4MethyltransferasesIBA
01/2020 - 08/2014
4Bortezomib (Velcade)FDA Link
03/2019 - 02/2008
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2016 - 04/2005
4Chloroquine (Aralen)FDA LinkGeneric
03/2015 - 12/2012
4SurvivinIBA
08/2008 - 05/2006
4contortrostatinIBA
09/2005 - 01/2003
3Trastuzumab (Herceptin)FDA Link
12/2021 - 09/2009
3ProdrugsIBA
02/2020 - 01/2003
3Proteasome InhibitorsIBA
03/2019 - 06/2009
3AntigensIBA
08/2018 - 01/2012
3Reactive Oxygen Species (Oxygen Radicals)IBA
03/2016 - 01/2016
3Drug CombinationsIBA
12/2012 - 02/2008
3hypericinIBA
11/2011 - 05/2003
3epigallocatechin gallate (epigallocatechin-3-gallate)IBA
03/2011 - 10/2007
3Topoisomerase I InhibitorsIBA
03/2011 - 05/2003
3Endothelin-1 (Endothelin 1)IBA
03/2010 - 04/2005
3Cyclooxygenase 2 (Cyclooxygenase-2)IBA
09/2009 - 05/2005
3Small Interfering RNA (siRNA)IBA
02/2008 - 04/2007
3Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
02/2008 - 01/2004
3TamoxifenFDA LinkGeneric
04/2006 - 11/2002
2Biological ProductsIBA
12/2021 - 05/2014
2RNA (Ribonucleic Acid)IBA
01/2021 - 01/2020
2Phosphotransferases (Kinase)IBA
10/2020 - 11/2002
2Flucytosine (Ancobon)FDA Link
02/2020 - 01/2003
2Cytosine DeaminaseIBA
02/2020 - 01/2003
2bromopyruvateIBA
11/2018 - 01/2017
2VenomsIBA
11/2018 - 01/2005
2GuanineIBA
09/2018 - 08/2014
2Neoplasm Antigens (Tumor Antigens)IBA
08/2018 - 03/2008
2RolipramIBA
01/2018 - 05/2002
2Adenosine Triphosphate (ATP)IBA
01/2017 - 10/2007
2Neurotransmitter Agents (Neurotransmitter)IBA
12/2016 - 03/2016
2AutoantigensIBA
05/2015 - 01/2012
2Antimalarials (Antimalarial Agents)IBA
03/2015 - 12/2012
2Mefloquine (Lariam)FDA LinkGeneric
03/2015 - 12/2012
2quinolineIBA
03/2015 - 12/2012
2MicroRNAs (MicroRNA)IBA
05/2014 - 01/2014
2Biomarkers (Surrogate Marker)IBA
01/2013 - 08/2008
2HIV Protease InhibitorsIBA
12/2012 - 09/2009
2Cytotoxins (Cytolysins)IBA
11/2012 - 03/2011
2resiquimodIBA
05/2012 - 01/2012
2Matrix Metalloproteinases (MMPs)IBA
05/2011 - 01/2003
2TeaIBA
03/2011 - 06/2009
2Interleukin-8 (Interleukin 8)IBA
03/2010 - 11/2005
2Caspase 7IBA
06/2009 - 10/2007
2Proteasome Endopeptidase Complex (Proteasome)IBA
06/2009 - 11/2007
2Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
04/2006 - 12/2005
2Green Fluorescent ProteinsIBA
04/2006 - 12/2005
2Fibronectins (Fibronectin)IBA
07/2005 - 01/2003
2Protein Kinase CIBA
05/2003 - 11/2002
1Anti-Bacterial Agents (Antibiotics)IBA
01/2022
1pembrolizumabIBA
01/2022

Therapy/Procedure

37Therapeutics
12/2021 - 05/2003
20Drug Therapy (Chemotherapy)
11/2021 - 09/2005
7Radiotherapy
01/2020 - 11/2006
4Intranasal Administration
08/2019 - 11/2012
2Brachytherapy
11/2021 - 11/2018
2Salvage Therapy
11/2021 - 11/2011
2Immunotherapy
08/2018 - 05/2012
2Chemoradiotherapy
04/2018 - 12/2015
2Ventriculoperitoneal Shunt
09/2010 - 11/2006
1Length of Stay
01/2022